BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

Abstract Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients’ outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this wo...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Nature Portfolio 2024-03-01
سلاسل:	Nature Communications
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41467-024-46778-8
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!